OS Therapies Inc
Business
OS Therapies is a clinical-stage biopharmaceutical company developing immunotherapies and antibody-drug conjugates for osteosarcoma and other solid tumors. Its lead product candidate, OST-HER2, is a Listeria-based cancer immunotherapy expressing HER2 peptides that completed a Phase IIb trial meeting its primary endpoint with favorable overall survival data. The company also owns the OST-tADC platform, a tunable antibody-drug conjugate technology with pH-sensitive silicone linkers currently in preclinical development. OS Therapies is pursuing regulatory pathways with the FDA, EMA and MHRA for OST-HER2 approval and intends to expand the program to breast, esophageal and lung cancers.
Summary from 10-K filed 2026-03-31
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 |
|---|---|---|---|---|
| Research and development | 16 | 3 | 3 | |
| General and administrative | 12 | 4 | 1 | |
| Loss from operations | −29 | −7 | −4 | |
| Interest income | 249 | — | 2 | |
| Interest expense | — | −2 | −3 | |
| Non-operating income | — | 33,997 | — | |
| Non-operating expenses | −1 | −51,250 | — | |
| Change in fair value of warrant liability | 1 | — | — | |
| TOTAL OTHER INCOME/EXPENSE | −48,143 | −2 | −3 | |
| NET LOSS | −29 | −9 | −8 | |
| Cumulative Series A preferred stock dividend requirement | — | −31,250 | — | |
| NET LOSS available to common shareholders | −29 | −9 | −8 | |
| Weighted average # of shares (in Shares) | 29 | 7 | — | |
| Basic loss per common share outstanding (in Dollars per share) | −0.98 | −1.28 | −1.46 | |
| Diluted loss per common share outstanding (in Dollars per share) | −0.98 | −1.28 | −1.46 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 |
|---|---|---|---|---|---|
| Cash | 269,830 | 6 | 38,982 | — | |
| Prepaid expenses | 63,082 | — | — | — | |
| Total Current Assets | 332,912 | 6 | 790,032 | — | |
| Fixed assets (net) | 2,490 | 5,270 | 8,050 | — | |
| Patent (net of amortization) | 7 | — | — | — | |
| Total-Long Term Assets | 7 | 5,270 | — | — | |
| TOTAL ASSETS | 7 | 6 | 798,082 | — | |
| Accounts payable | 10 | 2 | 3 | — | |
| Accrued expenses | 1 | 521,010 | 162,500 | — | |
| Accrued payroll and payroll taxes related party | 36,792 | 97,257 | 112,137 | — | |
| Accrued payroll and payroll taxes | 1,279 | — | 33,543 | — | |
| Preferred dividends payable | 375,000 | 375,000 | 343,750 | — | |
| Warrant liability | — | 2 | — | — | |
| Total Current Liabilities | 12 | 5 | 25 | — | |
| TEDCO grant | 100,000 | 100,000 | 100,000 | — | |
| Total Long-Term Liabilities | 100,000 | 100,000 | 100,000 | — | |
| Total Liabilities | 12 | 5 | 25 | — | |
| Commitments and contingencies (See Note 6) | — | — | — | — | |
| Series A Convertible Preferred Stock, par value $0.001, 2,500,000 shares authorized; 392,500 and 1,775,750 issued and outstanding, respectively | 1 | 4 | — | — | |
| Total Mezzanine Equity | 1 | 4 | — | — | |
| Common Stock A, par value $0.001, 150,000,000 shares authorized; 37,113,082 and 20,869,908 issued and outstanding, respectively | 37,116 | 20,870 | 5,340 | — | |
| Preferred Stock, par value $0.001, 5,000,000 shares authorized; 0 and 0 shares outstanding, respectively | — | — | 1,302 | — | |
| Additional paid-in capital | 61 | 35 | — | — | |
| Accumulated deficit | −67 | −38 | −30 | — | |
| Total Stockholders Deficit | −6 | −3 | −24 | −18 | |
| TOTAL LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS DEFICIT | 7 | 6 | 798,082 | — |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 |
|---|---|---|---|---|
| Depreciation and amortization expense | 363,085 | 2,780 | — | |
| Amortization of debt discounts issuance and warrants | — | 1 | 3 | |
| Shares issued for services | — | 25,000 | — | |
| Shares issued for interest expense | — | 8,523 | — | |
| Commitment shares issued for equity line of credit | 568,235 | — | — | |
| Common shares issuance for services | 595,841 | — | — | |
| Stock-based compensation | 4 | 268,300 | — | |
| Amortization of non-cash prepaids | 1 | — | — | |
| Accounts payable | 8 | −1 | 1 | |
| Accrued expenses | 893,992 | 358,510 | 147,500 | |
| Accrued interest on convertible notes | — | 613,605 | 802,479 | |
| Accrued Payroll and payroll taxes | −59,186 | −48,423 | — | |
| Net cash used in operating activities | −14 | −7 | −3 | |
| Patent License Acquisition | −466,423 | — | — | |
| Net cash used in investing activities | −466,423 | — | 1,145 | |
| Prepaid warrants (net of fees) | 530,162 | — | — | |
| Common stock issuance (net of fees) | 8 | — | — | |
| Short-term borrowings | — | 250,000 | — | |
| Short-term loan repayments | — | −250,000 | — | |
| Sale of preferred stock | 1 | 6 | — | |
| Initial public offering (net of fees) | — | 5 | — | |
| Net proceeds from conversion of debt A, B, C, D, E & F | — | 2 | 3 | |
| Net cash provided by financing activities | 9 | 13 | 3 | |
| Net change in cash | −5 | 5 | −132,498 | |
| Cash paid for interest | — | — | — | |
| Discount on notes payable redemption premium | — | 750,500 | 2 | |
| Dividends payable | — | 31,250 | 125,000 | |
| Deemed dividend on Series A convertible preferred stock | — | 2 | — | |
| Mezzanine equity conversion (net of costs) | 4 | — | — | |
| Conversion of preferred stock to common stock | — | 1,302 | — | |
| Amortization of deferred offering costs | — | 751,050 | 142,664 | |
| Conversion of convertible notes into common stock | — | 25 | — | |
| Conversion of warrants into common stock | — | 411 | — | |
| Issuance of common stock to investor advisor settlement | — | 320 | — | |
| Conversion of make-whole liability to common stock | — | 130,000 | — | |
| Clawback of common stock for over issuance | — | −670 | — | |
| Common stock issued for patent purchase | 6 | — | — | |
| Reclassification of warrants liability to equity | 878,153 | — | — | |
| Shares issued for prepaid services | 1 | — | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is OS Therapies Inc's CIK number?
OS Therapies Inc's SEC CIK number is 0001795091 (1795091). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find OS Therapies Inc's SEC filings?
All of OS Therapies Inc's EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did OS Therapies Inc last report earnings?
OS Therapies Inc (OSTX) most recently filed an earnings 8-K with the SEC on Aug 19, 2025, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001213900-25-078152). This is OS Therapies Inc's most recent earnings filing of record — not a forecast of its next earnings date.
What is OS Therapies Inc's most recent earnings 8-K?
OS Therapies Inc's latest earnings 8-K (Item 2.02) was filed Aug 19, 2025 under accession 0001213900-25-078152. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View OS Therapies Inc's latest earnings 8-K →
Look up any company's CIK number →